Success Metrics

Clinical Success Rate
76.9%

Based on 10 completed trials

Completion Rate
77%(10/13)
Active Trials
11(33%)
Results Posted
40%(4 trials)
Terminated
3(9%)

Phase Distribution

Ph phase_2
6
18%
Ph early_phase_1
2
6%
Ph not_applicable
13
39%
Ph phase_1
7
21%

Phase Distribution

9

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution28 total trials
Early Phase 1First-in-human
2(7.1%)
Phase 1Safety & dosage
7(25.0%)
Phase 2Efficacy & side effects
6(21.4%)
N/ANon-phased studies
13(46.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

52.6%

10 of 19 finished

Non-Completion Rate

47.4%

9 ended early

Currently Active

11

trials recruiting

Total Trials

33

all time

Status Distribution
Active(11)
Completed(10)
Terminated(9)
Other(3)

Detailed Status

Completed10
Recruiting6
Withdrawn6
Active, not recruiting5
unknown3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
33
Active
11
Success Rate
76.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (7.1%)
Phase 17 (25.0%)
Phase 26 (21.4%)
N/A13 (46.4%)

Trials by Status

unknown39%
recruiting618%
withdrawn618%
active_not_recruiting515%
completed1030%
terminated39%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT02526368Early Phase 1

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting
NCT04540107Phase 1

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting
NCT04286386

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

Active Not Recruiting
NCT02359565Phase 1

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Active Not Recruiting
NCT04908709Not Applicable

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

Recruiting
NCT03933670Phase 2

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Recruiting
NCT03830151Phase 1

Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

Recruiting
NCT05720624Phase 1

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Withdrawn
NCT02208362Phase 1

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Active Not Recruiting
NCT03581500Phase 2

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Withdrawn
NCT01653093Not Applicable

3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer

Active Not Recruiting
NCT04638998

Assessing Neuroinflammation in GWI Using MRS

Completed
NCT06457217

MRSI Evaluation for Minor Stroke With Large Vessel Occlusion

Recruiting
NCT06090630Early Phase 1

MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer

Completed
NCT03565367Phase 1

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Completed
NCT00474604Not Applicable

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

Completed
NCT01992861

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

Terminated
NCT03980535Not Applicable

New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality

Completed
NCT00963300Not Applicable

MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy

Withdrawn
NCT01342757Not Applicable

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
33